Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Specifically, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.
At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur’s pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team’s track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team.
This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.
At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur’s pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team’s track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team.
This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.
Location: United States, Massachusetts, Boston
Employees: 11-50
Founded date: 2016
Investment Type: Accelerator
Investment Stage: Series A
Portfolio 23
| Date | Name | Website | Total Raised | Location |
| 02.11.2022 | LianBio | lianbio.com | $635M | China, Sha... |
| 02.11.2022 | Juno Bio | junodx.com | - | United Sta... |
| 02.11.2022 | VivoSense | vivosense.com | $25M | United Sta... |
| 02.11.2022 | PolyCore T... | polycoretherapeutics.com | - | - |
| 02.11.2022 | avengebio | avengebio.com | $45M | United Sta... |
| 02.11.2022 | Zucara | zucara.ca | $70.25M | Canada, On... |
| 02.11.2022 | SURF BIO | surf.bio | $17.6M | - |
| 02.11.2022 | AsclepiX T... | asclepix.com | $50M | - |
| 02.11.2022 | Cerevasc | cerevasc.com | $114M | United Sta... |
| 02.11.2022 | AAVANTIBIO | aavantibio.com | $107M | United Sta... |
Show more
Persons 22
| Date | First Name | Last Name | Title | Location | |||
| - | Melissa | Rewolinski... | - | - | - | - | |
| - | Fred | Callori | - | linkedin.c... | - | f**d@xonto... | - |
| - | Ben | Askew | Partner, R... | linkedin.c... | - | b*n@xontog... | - |
| - | Takeru | Furuya, Ph... | - | - | - | - | |
| - | Holly | Purcell | - | - | - | - | |
| - | Takeru | Furuya | Senior Ass... | linkedin.c... | - | t****u@xon... | - |
| - | Ann | Taylor, M.... | - | - | - | - | |
| - | Gianna | Hoffman-Lu... | - | - | - | - | |
| - | Chris | Garabedian | Chairman a... | linkedin.c... | - | c***s@xont... | - |
| - | Shobha | Parthasara... | - | linkedin.c... | - | s****a@xon... | - |
Show more
Mentions in press and media 26
| Date | Title | Description |
| 10.09.2025 | Mercy BioAnalytics: $59 Million Closed To Advance Early Cancer Detection With Liquid Biopsy | Mercy BioAnalytics has announced the successful close of a $59 million Series B funding round to accelerate the development and commercialization of its early cancer detection technologies. The round was co-led by Novalis and Sozo Ventures,... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D CHICAGO–(BUSINESS WIRE)–May 14, 2025– Top decision-makers from across the biopharma ecosystem will con... |
| 03.04.2024 | Addex spin-off launched with USD63 million investment | Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Today the company announced that it will contribute a portfolio of... |
| 25.03.2024 | AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition | AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is acquiring Landos Biopharma, a clinical-stage biotech ... |
| 20.01.2022 | Investors disagree on whether digital health is in a bubble after another record funding haul in 2021 | If there were any doubts that digital health funding, especially in the U.S., is on a rocket ride straight to the stratosphere, they were removed with the latest funding report from CBInsights. Are we in a bubble? Is there irrational exuber... |
| 08.09.2021 | A-Alpha Bio Secures $20M Series A Financing to Accelerate Drug Discovery by Measuring Protein-Protein Interactions at Scale | When it comes to measuring protein-protein interactions and assisting pharma in the discovery of antibodies and molecular-glue targets, A-Alpha Bio's AlphaSeq platform is unmatched. AlphaSeq is enabling pharma companies to find the high-val... |
| 08.09.2021 | University of Washington spinout A-Alpha Bio snags $20M for protein-discovery platform | A-Alpha Bio founders David Younger (standing) and Randolph Lopez. (A-Alpha Bio Photo). A-Alpha Bio will build lab space in downtown Seattle and beef up its machine learning team with $20 million in new venture funding for its operation to i... |
| 13.05.2021 | Perceptive Advisors Closes $515M Early-Stage Biotech Fund | What You Should Know: – Perceptive Advisors and biotech accelerator Xontogeny, focused on seed investment, incubation and collaboration, have raised their second venture capital fund, the Perceptive Xontogeny Ventures Fund II (PXV Fund II),... |
| 12.05.2021 | Perceptive Advisors unveils $515M fund, its 2nd for early-stage biotechs | After 20 years of backing clinical-stage biotechs, Perceptive Advisors took a leap in 2019, teaming up with Chris Garabedian’s Xontogeny to invest in earlier-stage companies. Less than 18 months later, that crew is back for round two, with ... |
| 12.05.2021 | Perceptive Advisors unveils $515M fund, its 2nd for early-stage biotechs Remarque Systems: Content Hub | After 20 years of backing clinical-stage biotechs, Perceptive Advisors took a leap in 2019, teaming up with Chris Garabedian’s Xontogeny to invest in earlier-stage companies. Less than 18 months later, that crew is back for round two, with ... |
Show more